Retrospective cohort evaluation study in terms of cardiovascular and metabolic diseases in chronic hepatitis B patients
Author:
Open Access
- 3 October 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1426196
Abstract
Background: Chronic hepatitis B (CHB) and nucleotide analogues [entecavir (ETV) and tenofovir disoproxil fumarate (TDF)] used in its treatment have been shown to affect metabolic parameters in many studies. In this study, we aimed to investigate the effects of metabolic events associated with CHB and nucleotide analogues (NAs) used in CHB treatment on ischemic heart diseases (IHD) and cardiovascular diseases (CVD).Methods: This retrospective study was conducted between June 2022 and January 2024 with a total of 241 patients diagnosed with non-cirrhotic CHB in the gastroenterology outpatient clinic, 96 of whom did not receive hepatitis B treatment, 110 of whom received TDF, and 35 of whom received ETV treatment. Patients were evaluated in terms of metabolic, CVD, and hepatology depending on whether they received antiviral treatment or not. In our study, the triglyceride-glucose (TyG) index and triglyceride-to-high-density lipoprotein cholesterol ratio (TG/HDL-C) were calculated in patients to evaluate potential risk factors for CVD. Again, while the total cholesterol-to-HDL-C ratio (TC/HDL-C), which is associated with CVD\IHD, was evaluated, the ‘4-factor fibrosis index’ (FIB-4) score, which is a non-invasive indicator of liver fibrosis, was also evaluated.Results: Diabetes mellitus (DM), fasting blood sugar (FBS), oral antidiabetic drug (OAD) usage rate, and insulin usage rate were high in patients receiving ETV treatment. The TyG index of patients receiving ETV was higher than patients in the other group (p = 0.035; p<0.05). It was determined that the probability of detecting ETV treatment in patients with a TG/HDL-C ratio of ≥1.82 cut-off value was 4.250 times higher. The odds ratio for TG/HDL-C measurements was 4.250 (95% CI: 1.384–13.054). FIB-4 score, which is a non-invasive indicator of liver fibrosis, was found to be higher in patients receiving ETV than in other groups.Conclusion: In patients with CHB, a relationship was observed between markers used to predict CVD risk, such as the TyG index and TG/HDL-C ratio. The group with high levels of these two markers and a high potential for developing CVD was patients receiving ETV treatment. In this first study in the literature showing the relationship between CHB and CVD, we found that the relative risk of CVD was increased in patients using ETV.Keywords
This publication has 33 references indexed in Scilit:
- Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysisEuropean Journal of Clinical Pharmacology, 2024
- Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeksAlimentary Pharmacology & Therapeutics, 2023
- Triglyceride-glucose index associated with the risk of cardiovascular disease: the Kailuan studyEndocrine, 2021
- Value of triglyceride-glucose index for the estimation of ischemic stroke risk: Insights from a general populationNutrition, Metabolism and Cardiovascular Diseases, 2020
- Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk ConsortiumThe Lancet, 2019
- Systematic review: chronic viral hepatitis and metabolic derangementAlimentary Pharmacology & Therapeutics, 2019
- 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromesEuropean Heart Journal, 2019
- Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet, 2018
- Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation studyThe Lancet, 2018
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009